149 related articles for article (PubMed ID: 35534308)
1. Surgical management of BRCA-mutation carriers: A single institution experience.
Gentile D; Losurdo A; Sagona A; Zuradelli M; Gatzemeier W; Barbieri E; Testori A; Errico V; Bianchi P; Biondi E; Torrisi R; Santoro A; Tinterri C
Eur J Surg Oncol; 2022 Aug; 48(8):1706-1712. PubMed ID: 35534308
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
Wang C; Lin Y; Zhu H; Zhou Y; Mao F; Huang X; Zhou X; Cao X; Sun Q
Breast Cancer; 2022 Mar; 29(2):314-323. PubMed ID: 34766244
[TBL] [Abstract][Full Text] [Related]
4. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
Davey MG; Davey CM; Ryan ÉJ; Lowery AJ; Kerin MJ
Breast; 2021 Apr; 56():26-34. PubMed ID: 33582622
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
Shubeck S; Sevilimedu V; Berger E; Robson M; Heerdt AS; Pilewskie ML
Ann Surg Oncol; 2022 Aug; 29(8):4706-4713. PubMed ID: 35585432
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Valachis A; Nearchou AD; Lind P
Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
10. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
Khansa I; Wang D; Coriddi M; Tiwari P
Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
Perabò M; Fink V; Günthner-Biller M; von Bodungen V; Friese K; Dian D
Arch Gynecol Obstet; 2014 Jun; 289(6):1325-30. PubMed ID: 24389920
[TBL] [Abstract][Full Text] [Related]
12. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
Vallard A; Magné N; Guy JB; Espenel S; Rancoule C; Diao P; Deutsch E; Rivera S; Chargari C
Br J Radiol; 2019 May; 92(1097):20170657. PubMed ID: 30810334
[TBL] [Abstract][Full Text] [Related]
13. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
[TBL] [Abstract][Full Text] [Related]
14. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
15. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
16. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
17. Breast-conserving therapy is safe both within
Huang X; Cai XY; Liu JQ; Hao WW; Zhou YD; Wang X; Xu Y; Chen C; Lin Y; Wang CJ; Song Y; Sun Q
Gland Surg; 2020 Jun; 9(3):775-787. PubMed ID: 32775268
[TBL] [Abstract][Full Text] [Related]
18. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
19. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer after bilateral risk-reducing mastectomy.
Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
